On September 14, 2023, the Board of Directors of Kronos Bio, Inc. (Company) appointed Sandra A. Gardiner as the company?s interim Chief Financial Officer, effective at the close of business on September 15, 2023. Ms. Gardiner, age 57, served as the Chief Financial Officer, Executive Vice President of Finance and Administration and Treasurer of Pulse Biosciences, Inc. from November 2019 through December 2022. Ms. Gardiner also served as the Secretary of Pulse Biosciences from November 2019 until October 2021.

Prior to joining Pulse Biosciences, Ms. Gardiner served as Executive Vice President, Finance, and Chief Financial Officer of Cutera, Inc. from July 2017 to November 2019. Prior to that, Ms. Gardiner served as Vice President, Finance, Chief Financial Officer and Corporate Secretary of Tria Beauty, Inc. from April 2015 until it was acquired in April 2017. Ms. Gardiner has been serving as the acting Chief Financial Officer of Anebulo Pharmaceuticals, Inc. since March 2023 under a master services agreement between Potrero Hill Advisors, LLC and Anebulo, which agreement will end on September 28, 2023.

Ms. Gardiner has also served as Chief Financial Officer and Vice President of Finance of Aptus Endosystems, Inc.; Ventus Medical, Inc.; Vermillion, Inc.; and Lipid Sciences, Inc. Earlier in her career, Ms. Gardiner served in roles of increasing responsibility at Cardima, Inc., Comac, Inc. and Advanced Cardiovascular Systems, Inc. Ms. Gardiner currently serves on the board of directors of Levitas Bio and serves as Board Chair of the Valley Humane Society. She previously served on the board of directors of Lucira Health Inc. including serving as Audit Committee Chair and a member of the Nominating and Corporate Governance Committee. Ms. Gardiner holds a Bachelor of Arts degree in Management Economics from the University of California, Davis.

Ms. Gardiner is a partner of FLG Partners. Pursuant to a consulting agreement between the Company and FLG, dated September 8, 2023, FLG, through Ms. Gardiner, will provide CFO level services typical for a public company.